相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Metabolic plasticity of HIV-specific CD8+ T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection
Mathieu Angin et al.
NATURE METABOLISM (2019)
Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4+ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy
Nadia Madrid-Elena et al.
JOURNAL OF VIROLOGY (2018)
The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
Maria Rosa Lopez-Huertas et al.
SCIENTIFIC REPORTS (2017)
Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade
Katharina Grabmeier-Pfistershammer et al.
CLINICAL IMMUNOLOGY (2017)
Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
Carolina Gutierrez et al.
AIDS (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Galectin-9: From cell biology to complex disease dynamics
Sebastian John et al.
JOURNAL OF BIOSCIENCES (2016)
IL-7 Induces SAMHD1 Phosphorylation in CD4+T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle
Mayte Coiras et al.
CELL REPORTS (2016)
Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation
Mohamed Abdel-Mohsen et al.
PLOS PATHOGENS (2016)
The bitter side of sweet: the role of Galectin-9 in immunopathogenesis of viral infections
Shahzma Merani et al.
REVIEWS IN MEDICAL VIROLOGY (2015)
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Ole S. Sogaard et al.
PLOS PATHOGENS (2015)
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
Julian H. Elliott et al.
LANCET HIV (2015)
CTLA-4 and PD-1 pathway blockade: combinations in the clinic
Margaret K. Callahan et al.
FRONTIERS IN ONCOLOGY (2015)
HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat
Nancy M. Archin et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Thomas A. Rasmussen et al.
LANCET HIV (2014)
Galectin-9 in tumor biology: A jack of multiple trades
Roy Heusschen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2013)
HIV Infection Deregulates Tim-3 Expression on Innate Cells: Combination Antiretroviral Therapy Results in Partial Restoration
Constance A. M. Finney et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Quantitation of HIV DNA integration: Effects of differential integration site distributions on Alu-PCR assays
Troy Brady et al.
JOURNAL OF VIROLOGICAL METHODS (2013)
HIV-1 eradication strategies: design and assessment
Janet D. Siliciano et al.
CURRENT OPINION IN HIV AND AIDS (2013)
TIM-3 Does Not Act as a Receptor for Galectin-9
Judith Leitner et al.
PLOS PATHOGENS (2013)
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
Lishomwa C. Ndhlovu et al.
BLOOD (2012)
Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation
Liang Shan et al.
IMMUNITY (2012)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. M. Archin et al.
NATURE (2012)
Protective HIV-specific CD8+ T cells evade Treg cell suppression
Shokrollah Elahi et al.
NATURE MEDICINE (2011)
Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected
Carolina Gutierrez et al.
PLOS ONE (2011)
Tim3 binding to galectin-9 stimulates antimicrobial immunity
Pushpa Jayaraman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8(+) T-cell responses
Asier Saez-Cirion et al.
NATURE PROTOCOLS (2010)
Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways
Shuguang Bi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
R. Brad Jones et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection
Valentina Cecchinato et al.
JOURNAL OF IMMUNOLOGY (2008)
Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions
Keiko Nagahara et al.
JOURNAL OF IMMUNOLOGY (2008)
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells
Ana C. Anderson et al.
SCIENCE (2007)
Tim protein structures reveal a unique face for ligand binding
Ana C. Anderson et al.
IMMUNITY (2007)
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Lydie Trautmann et al.
NATURE MEDICINE (2006)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway
Y Kashio et al.
JOURNAL OF IMMUNOLOGY (2003)
分享论文
